Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.90 | Prev. Close $1.81 | Circuit Range N/A |
Day Range $1.80 - $1.90 | Year Range $0.53 - $2.61 | Volume 1,34,119 |
Average Traded $1.83 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
25-Feb-26 | $1.84 | $1.90 | +5.85% |
24-Feb-26 | $1.62 | $1.79 | +11.15% |
23-Feb-26 | $1.61 | $1.61 | +0.62% |
20-Feb-26 | $1.67 | $1.60 | -2.13% |
19-Feb-26 | $1.70 | $1.64 | -2.67% |
18-Feb-26 | $1.69 | $1.69 | -0.88% |
17-Feb-26 | $1.69 | $1.70 | -2.58% |